Autologous activated macrophages (MAK) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response.
Sutton
Laurent
L
Chaoui
Driss
D
Cazin
Bruno
B
Azar
Nabih
N
Chokri
Mohamed
M
Romet-Lemonne
Jean-Loup
JL
Maloum
Karim
K
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008262:Macrophage Activation; D008264:Macrophages / Q000637:transplantation*; D018365:Neoplasm, Residual; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab